As seen in preclinical models: PERJETA targets a different subdomain on the HER2 receptor than Herceptin does. When used together, PERJETA and Herceptin® (trastuzumab) provide a dual blockade of HER2-driven signaling pathways.1-3
PERJETA binds to subdomain II of HER2 receptors and blocks its ligand-dependent hetrodimerization with HER1, HER3, and HER4.1
PERJETA inhibits HER2:HER3 dimer formation and downstream signaling, suppressing HER2-mediated cell proliferation. It also augments antibody-dependent cell-mediated cytotoxicity (ADCC).1,8-10
Herceptin binds to subdomain IV and disrupts ligand-independent HER2 signaling. Herceptin also mediates ADCC.2,3
PERJETA and Herceptin together provide a dual blockade of HER2-driven signaling pathways.1,2
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.